What Is Tissue Engineering? How Stem Cells and Scaffolds Work Together to Rebuild Tissue

Stem cell therapy often gets discussed as if cells alone can rebuild damaged tissue, but in many of the field's most ambitious projects, cells are only one ingredient. Tissue engineering combines living cells, structural scaffolds, and biochemical signaling molecules to grow replacement tissue. NIBIB (NIH) defines it as combining "scaffolds, cells, and biologically active molecules into functional tissues."

Cells, Scaffolds, and Signals

Cells are the building blocks (stem cells or specialized cells expanded in culture); scaffolds give physical structure (natural proteins like collagen to synthetic biodegradable plastics) and relay signaling cues; signaling molecules and growth factors tell cells what to become. This separates tissue engineering from a simpler stem cell injection: building a three-dimensional environment that guides cells toward organized, functional tissue.

Bladder, Skin, Cartilage, and Cornea

The bladder is tissue engineering's landmark human success: Anthony Atala (now director of the Wake Forest Institute for Regenerative Medicine) implanted the first engineered organ in 1999 at Boston Children's Hospital; in April 2006 The Lancet reported long-term results of bladders grown from patients' own cells in seven children and young patients (ages four to nineteen) with spina bifida — some followed more than seven years, with improved incontinence and reduced kidney pressure in every patient.

Skin and cartilage are the steadiest, most clinically established wins; the cornea is a more recent genuine example: in 2025 researchers at Massachusetts Eye and Ear and Harvard Medical School (Ula Jurkunas) reported CALEC (cultivated autologous limbal epithelial cells) expanded phase 1/2 trial results in Nature Communications — corneal surface substantially or completely restored in the large majority at 12 months, no serious treatment-related adverse events.

The Trachea: A Cautionary Tale

The trachea is a cautionary tale: Paolo Macchiarini's early-2010s synthetic-scaffold windpipe transplants seeded with the patient's own stem cells were later found to involve misrepresented outcomes and patient deaths, leading to a criminal conviction in Sweden — a reminder that tissue requiring its own blood supply and mechanical stress is enormously harder to engineer, and that oversight and honest reporting matter.

Where the Field Is Headed

3D bioprinting, decellularized scaffolds, and vascularization research; thin tissues and those surviving on nearby blood vessels (bladder, cornea, skin) have succeeded; solid organs like kidney or liver remain a much longer-term goal.

Bottom Line

Tissue engineering represents one of the most tangible bridges between stem cell biology and real patient outcomes, precisely because it doesn't rely on cells alone — pairing cells with scaffolds and signaling molecules has built bladders functioning for over a decade and cornea grafts restoring sight in the large majority of a recent trial's participants; the trachea scandal is a sober reminder that tissue complexity and reporter integrity both matter enormously; the near-term frontier is solving unglamorous problems like blood supply and manufacturing consistency.